Fig. 5

Antitumor efficacy and immune response of Aposomes in the colon tumor models. a Tumor growth curves of CT26 colon tumor-bearing mice during treatment with an equivalent 3 mg/kg DOX dose of free DOX, DOXIL or Aposomes once every three days. b Tumor tissues stained with TUNEL after 13 days of treatment. c Expression levels of IAP in cancer cells after 13 days of treatment with free DOX, DOXIL or Aposomes. d Survival of mice during treatment with an equivalent 3 mg/kg DOX dose of free DOX, DOXIL or Aposomes once every three days. e The percentage of PD-L1⁺ tumor cells (CD45⁻PD-L1⁺) in the tumor tissues on day 13 after treatment. (f) The amount of HMGB1 and ATP in tumor supernatants on day 13 after treatment. g–j The percentage of g mature DCs (CD11c⁺CD40⁺CD86⁺), h cytotoxic T cells (CD45⁺CD3⁺CD8⁺) and i, j regulatory T cells (CD45 + CD3 + CD4 + CD25 +) in the tumor tissues on day 13 after treatment. k Relative amount of TNF-α, IFN-γ and IL-17 in tumor supernatants on day 13 after treatment. Significance was determined by Tukey − Kramer post-hoc and log-rank tests